OS Therapies Confirms It Will Release 2.5-Yr Overall Survival Data From Phase 2b Clinical Trial OST-HER2 In Prevention Or Delay Of Recurrence In Fully-Resected Pulmonary Metastatic Osteosarcoma During 2026 ASCO Annual Meeting